Kenjiro Tsuruoka1, Hidehito Horinouchi2, Yasushi Goto1, Shintaro Kanda1, Yutaka Fujiwara1, Hiroshi Nokihara1, Noboru Yamamoto1, Keisuke Asakura3, Kazuo Nakagawa3, Hiroyuki Sakurai3, Shun-Ichi Watanabe3, Koji Tsuta4, Yuichiro Ohe1. 1. Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. 2. Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: hhoriou@ncc.go.jp. 3. Division of Thoracic Surgery, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. 4. Division of Pathology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan; Department of Pathology and Laboratory Medicine, Kansai Medical University, Shinmachi 2-3-1, Hirakata, Osaka 573-1191, Japan.
Abstract
BACKGROUND: Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. METHODS: The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0-3]×stained area [0-100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. RESULTS: Among the 227 patients included in this study, the patient demographics were as follows: median age (range), 65 years (19-84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV): 79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC): 46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as follows: TC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%). CONCLUSIONS: PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.
BACKGROUND: Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. METHODS: The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0-3]×stained area [0-100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. RESULTS: Among the 227 patients included in this study, the patient demographics were as follows: median age (range), 65 years (19-84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV): 79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC): 46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as follows: TC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%). CONCLUSIONS:PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.
Authors: Vadim S Koshkin; Jorge A Garcia; Jordan Reynolds; Paul Elson; Cristina Magi-Galluzzi; Jesse K McKenney; Kumiko Isse; Evan Bishop; Laura R Saunders; Aysegul Balyimez; Summya Rashid; Ming Hu; Andrew J Stephenson; Amr F Fergany; Byron H Lee; Georges-Pascal Haber; Afshin Dowlati; Timothy Gilligan; Moshe C Ornstein; Brian I Rini; Mohamed E Abazeed; Omar Y Mian; Petros Grivas Journal: Clin Cancer Res Date: 2018-10-16 Impact factor: 12.531
Authors: Deborah Blythe Doroshow; Sheena Bhalla; Mary Beth Beasley; Lynette M Sholl; Keith M Kerr; Sacha Gnjatic; Ignacio I Wistuba; David L Rimm; Ming Sound Tsao; Fred R Hirsch Journal: Nat Rev Clin Oncol Date: 2021-02-12 Impact factor: 66.675
Authors: Sandip P Patel; Young Kwang Chae; Megan Othus; Francis J Giles; Donna E Hansel; Preet Paul Singh; Annette Fontaine; Manisha H Shah; Anup Kasi; Tareq Al Baghdadi; Marc Matrana; Zoran Gatalica; W Michael Korn; Jourdain Hayward; Christine McLeod; Helen X Chen; Elad Sharon; Edward Mayerson; Christopher W Ryan; Melissa Plets; Charles D Blanke; Razelle Kurzrock Journal: Clin Cancer Res Date: 2020-01-22 Impact factor: 12.531